In the first instance, Bindbridge is looking to develop a new broad spectrum non specific herbicide that can replace ...
Can you please introduce yourself and your role at LifeArc? As part of my Biochemistry degree at University of Leeds, I completed an industry placement at LifeArc. This was my first introduction to ...
Draupnir’s novel SORTAC platform expands reach of targeted protein degradation to extracellular proteins, demonstrating in vitro and in vivo efficacy against difficult-to-drug targetsStudy further ...
Targeted protein degradation has moved well beyond its prologue more than 20 years ago. 1 The number of publications describing different PROTACs (PROteolysis TArgeting Chimeras), molecular glues, and ...
SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation ...
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and ...
The end of the undruggable: Targeted protein degradation therapies open new frontiers in cancer care
Targeted protein degradation (TPD) therapy is a promising new class of targeted treatments. Based on a cell’s natural mechanism for eliminating diseased proteins, this therapy can combat hard-to-treat ...
Add Yahoo as a preferred source to see more of our stories on Google. Proteasomes are molecular machines for breaking down proteins. Drugmakers are working to coopt this process with targeted ...
Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results